Genetics of schizophrenia: What do we know?

Current Psychiatry

Volumn 12, Issue 3, 2013, Pages 25-33

  Zhang, Jian Ping ^a,b   Malhotra, Anil K ^a,b,c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b Northwell Health   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ARTICLE; CLINICAL PRACTICE; DISRUPTED IN SCHIZOPHRENIA 1 GENE; DOPAMINE RECEPTOR D2 GENE; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DYSTROBEVIN BINDING PROTEIN 1 GENE; EXTRAPYRAMIDAL SYMPTOM; GENE; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GRANULOCYTOSIS; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PHARMACOGENETICS; SCHIZOPHRENIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA; WEIGHT GAIN; ZINC FINGER PROTEIN 804A GENE;

EID: 84875774639     PISSN: 15378276     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003;60(12):1187-1192.
2. de Leon J. AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn. 2006; 6(3):277-286.
3. Psychiatric GWAS Consortium Coordinating Committee; Cichon S, Craddock N, Daly M, et al. Genomewide association studies: history, rationale, and prospects for psychiatric disorders. Am J Psychiatry. 2009;166(5):540-556.
4. Millar JK, Wilson-Annan JC, Anderson S, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet. 2000;9(9):1415-1423.
5. Porteous DJ, Millar JK, Brandon NJ, et al. DISC1 at 10: connecting psychiatric genetics and neuroscience. Trends Mol Med. 2011;17(12):699-706.
6. Schumacher J, Laje G, Abou Jamra R, et al. The DISC locus and schizophrenia: evidence from an association study in a central European sample and from a meta-analysis across different European populations. Hum Mol Genet. 2009;18(14):2719-2727.
7. Mathieson I, Munafó MR, Flint J, et al. Meta-analysis indicates that common variants at the DISC1 locus are not associated with schizophrenia. Mol Psychiatry. 2012; 17(6):634-641.
8. Straub RE, Jiang Y, MacLean CJ, et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet. 2002;71(2):337-348.
9. Allen NC, Bagade S, McQueen MB, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet. 2008;40(7):827-834.
10. Burdick KE, Lencz T, Funke B, et al. Genetic variation in DTNBP1 influences general cognitive ability. Hum Mol Genet. 2006;15(10):1563-1568.
11. Zhang JP, Burdick KE, Lencz T, et al. Meta-analysis of genetic variation in DTNBP1 and general cognitive ability. Biol Psychiatry. 2010;68(12):1126-1133.
12. Lencz T, Morgan TV, Athanasiou M, et al. Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry. 2007;12(6):572-580.
13. O'Donovan MC, Craddock N, Norton N, et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet. 2008;40(9):1053-1055.
14. Girgenti MJ, LoTurco JJ, Maher BJ. ZNF804a regulates expression of the schizophrenia-associated genes PRSS16, COMT, PDE4B, and DRD2. PLoS One. 2012;7(2):e32404.
15. Lencz T, Szeszko PR, DeRosse P, et al. A schizophrenia risk gene, ZNF804A, influences neuroanatomical and neurocognitive phenotypes. Neuropsychopharmacology. 2010;35(11):2284-2291.
16. International Schizophrenia Consortium; Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460(7256):748-752.
17. Stefansson H, Ophoff RA, Steinberg S, et al. Common variants conferring risk of schizophrenia. Nature. 2009;460(7256):744-747.
18. Handel AE, Ramagopalan SV. The potential role of major histocompatibility complex class I in schizophrenia. Biol Psychiatry. 2010;68(7):e29-e30.
19. Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium. Genome-wide association study identifies five new schizophrenia loci. Nat Genet. 2011; 43(10):969-976.
20. Gallego JA, Gordon ML, Claycomb K, et al. In vivo microRNA detection and quantitation in cerebrospinal fluid. J Mol Neurosci. 2012;47(2):243-248.
21. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461(7265): 747-753.
22. Walsh T, McClellan JM, McCarthy SE, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science. 2008;320(5875): 539-543.
23. Rees E, Kirov G, O'donovan MC, et al. De novo mutation in schizophrenia. Schizophr Bull. 2012;38(3):377-381.
24. Malhotra AK, Buchanan RW, Kim S. Allelic variation in the promotor region of the dopamine D2 receptor gene and clozapine response. Schizophr Res. 1999;36:92-93.
25. Lencz T, Robinson DG, Xu K, et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry. 2006;163, 3, 529-531.
26. Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a metaanalysis. Am J Psychiatry. 2010;167(7):763-772.
27. Zhang JP, Malhotra AK. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol. 2011;7(1):9-37.
28. Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet. 2000;355(9215): 1615-1616.
29. Schumacher J, Schulze TG, Wienker TF, et al. Pharmacogenetics of the clozapine response. Lancet. 2000; 356(9228):506-507.
30. Lavedan C, Licamele L, Volpi S, et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry. 2009;14(8):804-819.
31. Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41(7):816-819.
32. Athanasiou MC, Dettling M, Cascorbi I, et al. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry. 2011;72(4):458-463.
33. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet. 2002;359(9323): 2086-2087.
34. Sicard MN, Zai CC, Tiwari AK, et al. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics. 2010;11(11):1561-1571.
35. Malhotra AK, Correll CU, Chowdhury NI, et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry. 2012;69(9):904-912.
36. Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl). 2004;174(4):477-489.
37. Zhang JP, Malhotra AK. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol. 2011;7(1): 9-37.
38. Patsopoulos NA, Ntzani EE, Zintzaras E, et al. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics. 2005;15(3):151-158.
39. de Leon J. AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn. 2006;6(3): 277-286.
40. Mitchell PB, Meiser B, Wilde A, et al. Predictive and diagnostic genetic testing in psychiatry. Psychiatr Clin North Am. 2010;33(1):225-243.
41. Rundell JR, Staab JP, Shinozaki G, et al. Pharmacogenomic testing in a tertiary care outpatient psychosomatic medicine practice. Psychosomatics. 2011;52(2):141-146.
42. Malhotra AK, Zhang JP, Lencz T. Pharmacogenetics in psychiatry: translating research into clinical practice. Mol Psychiatry. 2012;17(8):760-769.